Search

Search Constraints

You searched for: Author/Creator Boster, Aaron

Search Results

1. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. (April 2022)

2. Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies. (November 2020)

5. Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial. Issue 11 (21st March 2014)

8. Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years. Issue 4 (December 2020)

9. Toward Precision Phenotyping of Multiple Sclerosis. Issue 6 (30th November 2022)